On the occasion of International Parkinson's Disease Day, Ms. Shen, the first Chinese recipient of UniXell Bio's autologous stem cell-derived drug UX-DA001, participated in a public science event at Ruijin Hospital, sharing her recovery progress one
On February 22, UniXell Bio's investigational autologous iPSC (induced pluripotent stem cell)-derived cell therapy UX-DA001 for Parkinson's disease received formal IND approval from the U.S. FDA, marking it as the world's first iPSC-based autologous
On December 20, 2024, Shanghai UniXell Biotech Co.,Ltd("UniXell Bio") received implicit approval from China's Center for Drug Evaluation (CDE) (Application No.: CXSL2400673) for its investigational iPSC-derived cell therapy product UX-DA001 (human mi
The autologous stem cell therapy project for Parkinson's disease launched this time will carry out a series of scientific research-clinical cooperation in strict compliance, including the establishment of iPSC libraries. It is reported that after the
On March 14, 2022, Shanghai UniXell Biotechnology Co., Ltd. (hereinafter referred to as "UniXell "), a leading company dedicated to the development of pluripotent stem cell drugs, announced the completion of nearly 200 million yuan in financing. This
On the occasion of International Parkinson's Disease Day, Ms. Shen, the first Chinese recipient of UniXell Bio's autologous stem cell-derived drug UX-DA001, participated in a public science event at Ruijin Hospital, sharing her recovery progress one
On February 22, UniXell Bio's investigational autologous iPSC (induced pluripotent stem cell)-derived cell therapy UX-DA001 for Parkinson's disease received formal IND approval from the U.S. FDA, marking it as the world's first iPSC-based autologous
On December 20, 2024, Shanghai UniXell Biotech Co.,Ltd("UniXell Bio") received implicit approval from China's Center for Drug Evaluation (CDE) (Application No.: CXSL2400673) for its investigational iPSC-derived cell therapy product UX-DA001 (human mi
The autologous stem cell therapy project for Parkinson's disease launched this time will carry out a series of scientific research-clinical cooperation in strict compliance, including the establishment of iPSC libraries. It is reported that after the
On March 14, 2022, Shanghai UniXell Biotechnology Co., Ltd. (hereinafter referred to as "UniXell "), a leading company dedicated to the development of pluripotent stem cell drugs, announced the completion of nearly 200 million yuan in financing. This
Recently, Shanghai UniXell Biotechnology Co., LTD. (UniXell), a leader in the field of pluripotent stem cell drug development, announced the completion of tens of millions of yuan angel round financing. This round of financing was led by Taifu Capita
